八段锦联合持续气道正压通气治疗老年阻塞性睡眠呼吸暂停低通气综合征的临床研究

Clinical study of Baduanjin combined with continuous positive airway pressure for obstructive sleep apnea-hypopnea syndrome in elderly patients

目的:观察八段锦联合持续气道正压通气(CPAP)治疗老年阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的临床疗效。方法:将90例老年OSAHS患者随机分为对照组和试验组,两组均给予健康教育、饮食及生活干预,对照组予CPAP治疗,治疗组在此基础上进行八段锦功法练习,两组均连续治疗12周。比较两组OSAHS老年患者Epworth嗜睡量表(ESS)评分、睡眠呼吸暂停呼吸暂停低通气指数(AHI)、最长呼吸暂停持续时间、最低血氧饱和度(LSaO_(2)),以及肿瘤坏死因子-α(TNF-α)、白细胞介素-18(IL-18)、丙二醛(MDA)和超氧化物歧化酶(SOD)水平。结果:与本组治疗前比较,治疗后两组ESS评分、AHI、最长呼吸暂停时间、MDA、TNF-α和IL-18均显著下降(P<0.05),LSaO_(2)和SOD显著上升(P<0.05);治疗后与对照组同期比较,试验组ESS评分、AHI、最长呼吸暂停时间、MDA、TNF-α和IL-18均显著下降(P<0.05),LSaO_(2)和SOD显著上升(P<0.05)。结论:八段锦联合CPAP治疗老年OSAHS临床疗效更显著。

Objective: To observe the clinical effect of Baduanjin combined with continuous positive airway pressure(CPAP) for obstructive sleep apnea-hypopnea syndrome(OSAHS) in elderty patients. Methods: A total of 90 cases of OSAHS patients were randomly divided into the treatment group and the control group. Both groups were given intervention of diet and life;the control group was additionally given continuous positive airway pressure, and the treatment group was additionally given Baduanjin training based on the treatment of the control group. After 12-week continuous treatment, score of Epworth sleepiness scale(ESS), apnea-hypopnea index(AHI), the longest apnea duration, lowest oxygen saturation(LSaO_(2)), tumor necrosis factor-α(TNF-α), interleukin-18(IL-18), malondialdehyde(MDA) and superoxide dismutase(SOD) were compared in the two groups before and after treatment. Results: When compared with those in the same group before treatment, score of ESS, AHI, the longest apnea duration, MDA, TNF-α, and IL-18 in the two groups were decreased after treatment(P<0.05), SOD and LSaO_(2)was increased(P<0.05). After treatment, score of ESS, AHI, the longest apnea duration,MDA, TNF-α, and IL-18 in the treatment group were lower than those in the control group(P<0.05), SOD and LSaO_(2)was higher(P<0.05). Conclusion: The therapy of Baduanjin combined with CPAP has significant curative effect in the treatment of OSAHS patients.